Cart
sales@molnova.com
JNK-IN-13
CAS No. 345986-38-1
JNK-IN-13( —— )
Catalog No. M37058 CAS No. 345986-38-1
JNK-IN-13 is a selective and potent JNK inhibitor that inhibits JNK3 and JNK2 and can be used in the study of diabetes, inflammation, and neurological disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 31 | In Stock |
|
| 25MG | 49 | In Stock |
|
| 50MG | 79 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJNK-IN-13
-
NoteResearch use only, not for human use.
-
Brief DescriptionJNK-IN-13 is a selective and potent JNK inhibitor that inhibits JNK3 and JNK2 and can be used in the study of diabetes, inflammation, and neurological disorders.
-
DescriptionJNK-IN-13 (compound 1) is a potent and selective JNK inhibitor with IC50s of 290 nM and 500 nM for JNK3 and JNK2, respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetJNK
-
RecptorJNK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number345986-38-1
-
Formula Weight286.74
-
Molecular FormulaC13H7ClN4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 31 mg/mL (108.11 mM )
-
SMILESClc1nccc(n1)C(C#N)c1nc2ccccc2s1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Serge Halazy, et al. Benzazole derivatives and their use as JNK modulators. EP1110957A1.
molnova catalog
related products
-
GNE-617
GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.
-
AS601245.2TFA (34598...
AS601245.2TFA (345987-15-7 free base) (AS601245.2TFA) is a cell-permeable Inhibitor of JNK (IC50s of 150, 220, and 70 nM for hJNK1, hJNK2, and hJNK3, respectively).
-
JNK Inhibitor VIII
JNK Inhibitor VIII is an ATP-competitive selective inhibitor of c-Jun N-terminal kinase (JNK)(IC50 values of 45 nM and 160 nM for JNK-1 and -2, respectively).
